sodium glucose cotransporter

Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease
Odette S Reifsnider, Anuraag R Kansal, Pranav K Gandhi, Lael Cragin, Sarah B Brand, Egon Pfarr, Kyle Fahrbach, Anastasia Ustyugova

BMJ Open Diabetes Research and Care May 2021, 9 (1) e001313; DOI: 10.1136/bmjdrc-2020-001313
Differential effects of sodium-glucose cotransporter 2 inhibitor and low-carbohydrate diet on body composition and metabolic profile in obese diabetic db/db mice
Toru Kusakabe, Shigefumi Yokota, Mika Shimizu, Takayuki Inoue, Masashi Tanaka, Ryuji Ohue-Kitano, Kazuya Muranaka, Hajime Yamakage, Hiromichi Wada, Koji Hasegawa, Noriko Satoh-Asahara

BMJ Open Diabetes Research and Care Sep 2020, 8 (1) e001303; DOI: 10.1136/bmjdrc-2020-001303
Insulin enhances renal glucose excretion: relation to insulin sensitivity and sodium-glucose cotransport
Ele Ferrannini, Ricardo Pereira-Moreira, Marta Seghieri, Eleni Rebelos, Aglécio L Souza, Valeria B Chueire, Caterina Arvia, Elza Muscelli

BMJ Open Diabetes Research and Care May 2020, 8 (1) e001178; DOI: 10.1136/bmjdrc-2020-001178
Response evaluation of SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus using ¹⁸F-FDG PET/MRI
Sazan Rasul, Barbara Katharina Geist, Helmut Brath, Pascal Baltzer, Lalith Kumar Shiyam Sundar, Verena Pichler, Markus Mitterhauser, Alexandra Kautzky-Willer, Marcus Hacker

BMJ Open Diabetes Research and Care Mar 2020, 8 (1) e001135; DOI: 10.1136/bmjdrc-2019-001135
Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier’s gangrene
Jeff Yufeng Yang, Tiansheng Wang, Virginia Pate, John B Buse, Til Stürmer

BMJ Open Diabetes Research and Care Jan 2020, 8 (1) e000985; DOI: 10.1136/bmjdrc-2019-000985
Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
Shih-Chieh Shao, Yi-Han Lin, Kai-Cheng Chang, Yuk-Ying Chan, Ming-Jui Hung, Yea-Huei Kao Yang, Edward Chia-Cheng Lai

BMJ Open Diabetes Research and Care Dec 2019, 7 (1) e000742; DOI: 10.1136/bmjdrc-2019-000742
Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA
Mukul Singhal, Hiangkiat Tan, Craig I Coleman, Michelle Han, Chi Nguyen, Michael Ingham

BMJ Open Diabetes Research and Care Nov 2019, 7 (1) e000704; DOI: 10.1136/bmjdrc-2019-000704
Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet
Liang Xu, Naoto Nagata, Guanliang Chen, Mayumi Nagashimada, Fen Zhuge, Yinhua Ni, Yuriko Sakai, Shuichi Kaneko, Tsuguhito Ota

BMJ Open Diabetes Research and Care Oct 2019, 7 (1) e000783; DOI: 10.1136/bmjdrc-2019-000783
Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors
Gian Paolo Fadini, Mayur Sarangdhar, Fabrizio De Ponti, Angelo Avogaro, Emanuel Raschi

BMJ Open Diabetes Research and Care Oct 2019, 7 (1) e000725; DOI: 10.1136/bmjdrc-2019-000725
Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study
Stéphane Pintat, Peter Fenici, Niklas Hammar, Linong Ji, Kamlesh Khunti, Jesús Medina, Fengming Tang, Eric Wittbrodt, Filip Surmont

BMJ Open Diabetes Research and Care Mar 2019, 7 (1) e000627; DOI: 10.1136/bmjdrc-2018-000627

Log in using your username and password

Main menu

Log in using your username and password

You are here

sodium glucose cotransporter